ProPhase Labs, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders??? Equity (Tables)

Stockholders’ Equity (Tables)

12 Months Ended

Dec. 31, 2022

The following table summarizes stock options activity during Fiscal 2022 and 2021 (in thousands, except per share data).


	Number of Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)	Total Intrinsic Value
Outstanding as of January 1, 2021	3,795	2.21		3.4	$	26,441
Granted	1,825	7.29		6.2	—
Forfeited	(505)	8.50		0	—
Expired	(5)	1.39		0	—
Outstanding as of December 31, 2021	5,110	$	3.27	3.4	$	20,820
Granted	1,095	9.92		7	—
Exercised	(1,833)	1.29		0	—
Forfeited	(420)	1.56		0	—
Outstanding as of December 31, 2022	3,952	$	5.35	4	$	20,379
Options vested and exercisable	2,961	$	4.06	3.2	$	17,257

Summary of Weighted Average Assumptions Used in Determining Fair Value of Options

The following table summarizes weighted average assumptions used in determining the fair value of the stock options at the date of grant during Fiscal 2022 and 2021:


	For the years ended December 31,
	2022			2021
Exercise price	$	10.03		$	7.29
Expected term (years)	4.5			4
Expected stock price volatility	79		%	79		%
Risk-free rate of interest	2.5%			0.8		%
Expected dividend yield (per share)	0		%	0		%

Schedule of Warrant Activity

The following table summarizes warrant activities during Fiscal 2022 and 2021 (in thousands, except per share data):


	Number of Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding as of January 1, 2021	450	$	3.22	2.7
Warrants granted	455	12.83		3
Cashless exercise	(50)	5.00		0
Outstanding as of December 31, 2021	855	$	8.23	1.9
Warrants granted	—	—		0
Outstanding as of December 31, 2022	855	$	8.23	1.9
Warrants vested and exercisable	855	$	8.23	1.9

Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants

The following table summarizes weighted average assumptions used in determining the fair value of the warrants at the date of grant during Fiscal 2022 and Fiscal 2021:


	For the years ended December 31,
	2022			2021
Exercise price	$	—		$	12.83
Expected term (years)	0			3.0
Expected stock price volatility	0%			81%
Risk-free rate of interest	0.0%			0.2		%
Expected dividend yield (per share)	0		%	0		%